AKT is a therapeutic target in myeloproliferative neoplasms

The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K, and ERK signaling pathways. JAK inhibitors by themselves are inadequate in producing selective clonal suppression in MPN an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Khan, Irum, Huang, Zan, Wen, Qiang, Stankiewicz, Monika J., Gilles, Laure, Goldenson, Benjamin, Schultz, Rachael, Diebold, Lauren, Gurbuxani, Sandeep, Finke, Christy M., Lasho, Terra L., Koppikar, Priya, Pardanani, Animesh, Stein, Brady, Altman, Jessica K., Levine, Ross L., Tefferi, Ayalew, Crispino, John D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4023863/
https://ncbi.nlm.nih.gov/pubmed/23748344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.167
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares